Syndax Announces Participation at Two Upcoming Investor Conferences

WALTHAM, Mass., Feb. 1, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in two upcoming investor conferences:

• A fireside chat at the Guggenheim 6th Annual Biotechnology Conference at 10:00 a.m. ET on Thursday, February 8, 2024 in New York, NY.
• A fireside chat at the Citi 2024 Virtual Oncology Leadership Summit at 2:00 p.m. ET on Wednesday, February 21, 2024.

A live webcast of the fireside chats can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the events will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.

Syndax Contacts

Sharon Klahre
Syndax Pharmaceuticals, Inc.
[e-mail]
Tel [phone]

SNDX-G

View original content:https://www.prnewswire.com/news-releases/syndax-announces-participation-at-two-upcoming-investor-conferences-302051306.html

SOURCE Syndax Pharmaceuticals, Inc.

Copyright 2024 PR Newswire